All In Biotech

Free tool

FAERS Monitor: Sandostatin Lar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021008 or its brand name (Sandostatin Lar, Octreotide Acetate). Reports on generic versions are filed under their own applications.

Reports

19,732

Serious

14,449

73% of reports

Hospitalization

6,326

Death reported

4,290

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3,250
  • diarrhoea2,897
  • needle issue2,397
  • fatigue2,316
  • malaise2,248
  • blood pressure increased2,087
  • pain1,838
  • nausea1,820
  • malignant neoplasm progression1,774
  • blood pressure systolic increased1,697
  • abdominal pain1,673
  • asthenia1,647
  • injection site pain1,574
  • weight decreased1,536
  • inappropriate schedule of product administration1,504

Reports by year received

View as table
YearReports
200428
200528
200648
200748
200858
2009112
2010170
2011178
2012280
2013293
2014911
20151,784
20162,378
20172,220
20182,307
20191,648
20202,147
20211,931
2022900
2023930
2024619
2025441
2026273

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,427 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood pressure systolic increasedSignal1,697101.596.8154,253
needle issueSignal2,39795.591.9206,002
malignant neoplasm progressionSignal1,77418.817.929,458
blood pressure increasedSignal2,08714.714.126,540
inappropriate schedule of product administrationSignal1,5049.08.510,633
abdominal painSignal1,6737.77.49,808
weight decreasedSignal1,5365.95.66,283
injection site painSignal1,5745.55.25,835
malaiseSignal2,2485.55.38,375
diarrhoeaSignal2,8974.84.68,949
astheniaSignal1,6474.74.54,836
deathSignal3,2504.03.97,696
painSignal1,8383.23.12,846
fatigueSignal2,3163.23.13,576
nauseaSignal1,8202.52.31,625

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.